Does Neupogen Boost White Blood Cell Counts?
Yes, Neupogen (filgrastim) works to increase white blood cell (WBC) counts, specifically neutrophils, which are the most common type of WBC. It is FDA-approved for treating neutropenia, a condition with low neutrophil levels that raises infection risk. Administered via injection, it stimulates bone marrow to produce more neutrophils, typically raising counts within days.[1][2]
How Quickly Does Neupogen Raise WBC Levels?
Neupogen often elevates absolute neutrophil counts (ANC, a key WBC measure) within 24-48 hours of the first dose. Peak effects occur around days 3-5, with ANC returning to normal ranges in most patients by day 4 after chemotherapy-induced neutropenia. Daily dosing continues until ANC exceeds 10,000 cells/mm³ for three days.[1][3]
What Conditions Is Neupogen Used For?
- Chemotherapy-induced neutropenia: Prevents infections after cancer treatments that suppress bone marrow.
- Bone marrow transplant: Speeds WBC recovery post-transplant.
- Severe chronic neutropenia: Treats congenital or idiopathic forms.
- Peripheral blood progenitor cell collection: Boosts WBCs for stem cell harvesting.[1][2]
It does not treat all WBC issues, like those from leukemia directly.
Common Side Effects on WBC Users
Most patients tolerate Neupogen well, but side effects include bone pain (up to 30% of users), fever, and spleen enlargement. Rare risks: acute respiratory distress syndrome or splenic rupture. WBC counts can overshoot, causing leukocytosis, which doctors monitor.[1][4] Patients report manageable pain, often relieved by acetaminophen.
How Does Neupogen Compare to Neulasta?
Neupogen requires daily injections, while Neulasta (pegfilgrastim), a longer-acting version, needs one dose per chemo cycle. Both raise WBCs effectively, but Neulasta sustains levels longer (up to 14 days). Neupogen costs less per treatment but involves more administrations.[2][5]
Who Makes Neupogen and When Do Patents Expire?
Amgen manufactures Neupogen, first approved in 1991. Key U.S. patents expired in 2015, enabling biosimilars like Zarxio (Sandoz) and Nivestym (Pfizer). Remaining pediatric exclusivity ended in 2015; no major patents block generics now.[6][7] Check DrugPatentWatch.com for latest expiration details.
Sources
[1]: Neupogen Prescribing Information (FDA)
[2]: MedlinePlus - Filgrastim
[3]: NEJM Study on Filgrastim Kinetics
[4]: Drugs.com - Neupogen Side Effects
[5]: ASCO Guidelines on Colony-Stimulating Factors
[6]: DrugPatentWatch.com - Neupogen
[7]: FDA Orange Book - Filgrastim Approvals